FSFarooq Saleem

Farooq Saleem

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Farooq Saleem has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    First identification of trigonelline in Guaiacum Officinale fruit and its dengue protease inhibition activity

    by Sadia Shoukat, Farooq Saleem, Saima Maher, Muhammad Saeed, Arshad Ali Shah, John Trant, M. Usman Mirza, Sarfraz Ahmad

    Although Dengue virus (DENV) continues to cause substantial global morbidity, no direct-acting antivirals are available for routine clinical use despite the viral NS2B–NS3 serine protease being a well-validated enzymatic target for small-molecule inhibition. Here we report, to our knowledge, the first identification (and HPLC quantification) of trigonelline (N-methylnicotinic acid) in Guaiacum officinale fruit and demonstrate its inhibition of the DENV-2 NS2B–NS3 protease (IC₅₀ = 76±3 μM). To explain this activity, we integrated unbiased molecular docking with molecular dynamics (MD) and end-point calculations. The MD-relaxed binding mode places the trigonelline carboxylate in a polar niche stabilized by a Ser135 and Tyr150 hydrogen-bond dyad, while the pyridinium ring engages an adjacent aromatic shelf (Tyr161 and Phe130) near the His51–Asp75–Ser135 catalytic triad. The low protein RMSD and low ligand drift suggest this is a persistent pose. MM/GBSA calculated affinity is dominated by van der Waals contributions, and a per-residue decomposition highlight stabilizing roles for Ser135, Tyr150, and Pro132, consistent with the observed contact pattern and supportive of target engagement. While the potency is moderate, it is consistent with a fragment-like chemotype in the protease substrate-binding cleft and provides a tractable entry point for derivatization. Contact-persistence and the energy decomposition suggest promising avenues for future structure–activity exploration, i.e., extension of the ligand into the S1/S2 subsites, reinforcement of aromatic contacts, and polarity management to increase hydrophobic collapse as a new opportunity for dengue protease inhibitor design.

  • Physicochemical and Bioassay Directed GC-MS Analyses of Chloroform Extract of Pteris cretica L.

    by Farooq Saleem, Rashad Mehmood, Tahir Javed Khan, Saeed-Ul Hassen, Saima Maher, Sarfraz Ahmad, Shagufta Perveen, Muhammad Azeem


  • Open Access

    Isolation of Antidiabetic Withanolides from Withania coagulans Dunal and Their In Vitro and In Silico Validation

    by Saima Maher, M. Iqbal Choudhary, Farooq Saleem, Saima Rasheed, Imran Waheed, Sobia Ahsan Halim, Muhammad Azeem, Iskandar Bin Abdullah, Matheus Froeyen, Muhammad Usman Mirza, et al.

    Withania coagulans (W. coagulans) is well-known in herbal medicinal systems for its high biological potential. Different parts of the plant are used against insomnia, liver complications, asthma, and biliousness, as well as it is reported to be sedative, emetic, diuretic, antidiabetic antimicrobial, anti-inflammatory, antitumor, hepatoprotective, antihyperglycemic, cardiovascular, immuno-suppressive and central nervous system depressant. Withanolides present in W. coagulans have attracted an immense interest in the scientific field due to their diverse therapeutic applications. The current study deals with chemical and biological evaluation of chloroform, and n-butanol fractions of W. coagulans. The activity-guided fractionation of both extracts via multiple chromatographic steps and structure elucidation of pure isolates using spectroscopies (NMR, mass spectrometry, FTIR and UV-Vis) led to the identification of a new withanolide glycoside, withacogulanoside-B (1) from n-butanol extract and five known withanolides from chloroform extract [withanolid J (2), coagulin E (3), withaperuvin C (4), 27-hydroxywithanolide I (5), and ajugin E (6)]. Among the tested compounds, compound 5 was the most potent α-glucosidase inhibitor with IC50 = 66.7 ± 3.6 µM, followed by compound 4 (IC50: 407 ± 4.5 µM) and compound 2 (IC50: 683 ± 0.94 µM), while no antiglycation activity was observed with the six isolated compounds. Molecular docking was used to predict the binding potential and binding site interactions of these compounds as α-glucosidase inhibitors. Consequently, this study provides basis to discover specific antidiabetic compounds from W. coagulans.